- CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors
- The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier
- The blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumors
- By crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central nervous system cancers annually
This year, about 25,050 adults (14,170 men and 10,880 women) will be diagnosed with malignant central nervous system (“CNS”) tumors – cancerous tumors that start in the spinal cord or brain. The figure represents an increase from an estimated 24,530 cases documented last year. Of these statistics, the American Society of Clinical Oncology (“ASCO”) notes that brain tumors account for 85-90% of all primary CNS tumors (https://ibn.fm/c9ThB). But despite this prevalence, the treatment of brain tumors has long been complicated by the brain’s internal workings.
A healthy human brain has a mechanism known as the blood-brain barrier that protects the active functions of the CNS and blocks toxins and microorganisms from passing through the highly picky semipermeable border. While this barrier promotes stability of the…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
